I7G0.F IPSEN SA SP.ADR 1/4/ EO 1

Healthcare Pharmaceuticals Frankfurt Exchange
41.20 EUR
Close of Nov 12, 2026
28.69 43.00
Market cap
EUR 13.6B
P/E
26.6x
P/B
2.90x
ROE
10.2%
Dividend yield
0.86%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is I7G0.F undervalued?

Graham number
Price41.20
Graham value22.27
Premium85.0%

I7G0.F trades 85.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IPSEN SA SP.ADR 1/4/ EO 1 fundamental analysis

No fundamental analysis for IPSEN SA SP.ADR 1/4/ EO 1 yet.

IPSEN SA SP.ADR 1/4/ EO 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IPSEN SA SP.ADR 1/4/ EO 1

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, fema…

Full company profile